Hoth Therapeutics receives Chinese patent for cancer tech

Hoth Therapeutics has announced the issuance of a Chinese patent for its innovative cancer cell-targeting technology. This patent protects the company's intellectual property related to novel therapies designed to combat cancer. The development marks a significant milestone for Hoth Therapeutics as it advances its pipeline of treatments for unmet medical needs. This patent is expected to strengthen the company's position in the biopharmaceutical market and support its ongoing efforts to develop effective cancer therapies.